GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: LY-3819469 | LY3819469
Compound class:
Nucleic acid
Comment: Lepodisiran (LY3819469) is an apolipoprotein A synthesis reducer. It is a GalNac-conjugated short interfering RNA (siRNA) that was designed to treat atherosclerotic cardiovascular disease in patients with elevated lipoprotein A [1-2].
|
| No information available. |
Summary of Clinical Use  |
| Eli Lilly are investigating the safety and clinical efficacy of lepodisiran (LY3819469) in volunteers with elevated lipoprotein A. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05565742 | A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] | Phase 2 Interventional | Eli Lilly and Company | ||
| NCT06292013 | A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Phase 3 Interventional | Eli Lilly and Company | ||
